FP
Flagship Pioneering Portfolio holdings
AUM
$268M
This Quarter Return
-11.42%
1 Year Return
-54.4%
3 Year Return
-51.2%
5 Year Return
+66.7%
10 Year Return
–
AUM
$2.57B
AUM Growth
+$2.57B
(-18%)
Cap. Flow
+$13.5M
Cap. Flow
% of AUM
0.52%
Top 10 Holdings %
Top 10 Hldgs %
99.98%
Holding
12
New
–
Increased
1
Reduced
–
Closed
1
Top Buys
| 1 |
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
|
$20M |
Top Sells
| 1 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
$6.55M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Moderna
MRNA
$9.37B
| $1.98B | 76.91% | 12,886,743 | – | – |
|
|
OMGA
2
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $176M | 6.85% | 29,225,579 +3,323,310 | +13% | +$20M |
|
3
Seres Therapeutics
MCRB
$166M
| $131M | 5.09% | 23,117,045 | – | – |
|
4
Sana Biotechnology
SANA
$777M
| $112M | 4.35% | 34,239,018 | – | – |
|
5
Foghorn Therapeutics
FHTX
$286M
| $78.6M | 3.05% | 12,674,120 | – | – |
|
6
Denali Therapeutics
DNLI
$2.23B
| $60.4M | 2.35% | 2,619,968 | – | – |
|
|
AXLA
7
DELISTED
Axcella Health Inc. Common Stock
AXLA
| $14M | 0.55% | 29,251,545 | – | – |
|
|
SGTX
8
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| $9.65M | 0.37% | 10,370,369 | – | – |
|
|
EVLO
9
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $9.11M | 0.35% | 50,427,328 | – | – |
|
|
SYRS
10
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $2.65M | 0.1% | 993,848 | – | – |
|
|
CDAK
11
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
| $618K | 0.02% | 3,540,636 | – | – |
|
|
RUBY
12
DELISTED
Rubius Therapeutics, Inc
RUBY
| – | – | -38,506,526 | Closed | -$6.55M |
|